Skip Nav Destination
Issues
1 September 2009
-
Cover Image
Cover Image
Bone marrow-derived neural progenitor/stem cells form neurospheres and express typical neural stem cell marker nestin. Immunofluorescence staining of the neurospheres reveals expression of nestin protein (green). Counterstaining of the nuclei with DAPI is depicted (blue). These adult neural stem cells manifest glioma tracking property mediated through chemokine CXC receptor 4 signaling. For details, see the article by Xu and colleagues on page 2746. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Issue Sections
Spotlight on Clinical Response
Review
Research Articles
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells
Duncan H. Mak; Wendy D. Schober; Wenjing Chen; Marina Konopleva; Jorge Cortes; Hagop M. Kantarjian; Michael Andreeff; Bing Z. Carter
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients
Windy Berkofsky-Fessler; Tri Q. Nguyen; Paul Delmar; Juliette Molnos; Charu Kanwal; Wanda DePinto; James Rosinski; Patricia McLoughlin; Steve Ritland; Mark DeMario; Krishna Tobon; John F. Reidhaar-Olson; Ruediger Rueger; Holly Hilton
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer
Shu Yang; Van Chanh Ngo; Guo Bin Lew; Lih Wen Valerie Chong; Swee Shean Lee; Wei Jie Richard Ong; Wei Ling Irene Lam; Choon Hua Thng; Heng Nung Koong; Hock Soo Ong; Alexander Chung; Pierce Chow; Jonathan Lee; Khee Chee Soo; Hung Huynh
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines
M. Pia Morelli; Amy M. Brown; Todd M. Pitts; John J. Tentler; Fortunato Ciardiello; Anderson Ryan; Juliane M. Jürgensmeier; S. Gail Eckhardt
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Frits van Rhee; Susann M. Szmania; Myles Dillon; Anne M. van Abbema; Xin Li; Mary K. Stone; Tarun K. Garg; JuMei Shi; Amberly M. Moreno-Bost; Rui Yun; Balaji Balasa; Bishwa Ganguly; Debra Chao; Audie G. Rice; Fenghuang Zhan; John D. Shaughnessy, Jr.; Bart Barlogie; Shmuel Yaccoby; Daniel E.H. Afar
Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis
Maria Vincenza Carriero; Immacolata Longanesi-Cattani; Katia Bifulco; Ornella Maglio; Liliana Lista; Antonio Barbieri; Giuseppina Votta; Maria Teresa Masucci; Claudio Arra; Renato Franco; Mario De Rosa; Maria Patrizia Stoppelli; Vincenzo Pavone
Corrections
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds
